Core Points - The inclusion of HPV vaccine in the national immunization program reflects the government's commitment to women's health and aims to accelerate the global goal of eliminating cervical cancer by 2030 [1][5][6] Group 1: HPV Vaccine Introduction and Strategy - The WHO's global strategy aims for 90% of girls to be vaccinated by age 15, 70% of women aged 35-45 to be screened, and 90% of diagnosed patients to receive treatment by 2030 [2] - Since the introduction of the HPV vaccine in China, annual vaccination doses and coverage rates have been increasing, but as of 2022, the first dose coverage was only 10.15% and the third dose was 6.21%, significantly below the global average [2][3] - The process of including the HPV vaccine in the national immunization program has gone through three phases over five years, starting with pilot programs and expanding to provincial and national levels [3][4] Group 2: Vaccine Production and Pricing - There are currently six HPV vaccines available in China, with significant price reductions observed, such as the two-valent HPV vaccine's price dropping to 27.5 yuan, which is less than one-tenth of its initial price [7][8] - The price of the two-valent HPV vaccine has decreased significantly since the introduction of domestic alternatives, making it more accessible and increasing the likelihood of its inclusion in the national immunization program [8][9] - Companies like Wantai and Watson have reported sufficient production capacity, with Wantai's two-valent HPV vaccine capable of producing 30 million doses annually [9][11] Group 3: Implementation and Public Awareness - Effective public awareness campaigns are essential to ensure high vaccination rates, addressing concerns about the differences between domestic and imported vaccines [12][14] - The government is encouraged to conduct thorough surveys to assess the target population's willingness to vaccinate and to implement a flexible supply mechanism based on actual demand [13][14] - A phased approach to vaccination is recommended to achieve the 90% target, focusing on systematic coverage of school-aged girls over several years [14]

Group 1: HPV Vaccine Inclusion in National Immunization Program - The National Health Commission announced the inclusion of HPV vaccination services for eligible girls in the national immunization program to enhance women's health protection [1][2] - Since 1978, China's immunization program has expanded from 4 vaccines to 14 vaccines preventing 15 infectious diseases [1] - HPV is a major cause of cervical cancer, and vaccination is a primary preventive measure, with existing vaccines effectively preventing over 70% of cervical cancer cases [1][2] Group 2: Cervical Cancer Statistics - In 2022, China reported 151,000 new cervical cancer cases, ranking fifth among female cancers, with 56,000 deaths, ranking sixth in female cancer mortality [2] Group 3: Free Vaccination Initiatives - Several regions have initiated free HPV vaccination programs, with Beijing starting free vaccinations for girls entering the first year of junior high school in 2025 [3] - As of August 2023, 18 provinces and several cities have included HPV vaccination in government initiatives, covering approximately 60% of eligible girls [3] Group 4: Market Dynamics and Company Performance - The inclusion of HPV vaccines in the national program is expected to improve public awareness and accessibility, potentially stabilizing sales for vaccine companies [4][5] - Companies like Watson Bio and Zhifei Biological have faced performance pressures due to declining public willingness to vaccinate and increased competition [7] - Watson Bio reported a revenue of 1.154 billion yuan in the first half of the year, down 19.47%, while Zhifei Biological's revenue was 4.919 billion yuan, down 73.06% [7] Group 5: Pricing and Competition - The first domestic two-valent HPV vaccine was priced at 499 yuan per dose, significantly lower than imported alternatives, which were priced over 1,300 yuan per dose [8] - The market for nine-valent HPV vaccines has become competitive, with companies like Zhifei Biological reducing prices and offering promotions to maintain market share [9]